Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies
Open Access

In Vitro Anticancer Activity of the Light Stable Zinc Isotope (64Zn) Compounds

PETER NOVAK, ALEXANDR BALAKIN and MAX TEMNIK
Anticancer Research December 2022, 42 (12) 5685-5698; DOI: https://doi.org/10.21873/anticanres.16077
PETER NOVAK
Vector Vitale LLC, North Miami Beach, FL, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: preclinical@vectorvitale.com
ALEXANDR BALAKIN
Vector Vitale LLC, North Miami Beach, FL, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MAX TEMNIK
Vector Vitale LLC, North Miami Beach, FL, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Graphic image of a Zn64 aspartate molecule. Schematic representation (A) and 3D model (B).

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Synthesis scheme of Zn64 aspartate from L-aspartic acid and 64Zn oxide enriched stable light isotope to 99.2% mass fraction of total zinc.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Graphic image of a Zn64 glutamate molecule. Schematic representation (A) and 3D model (B).

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Synthesis scheme of Zn64 aspartate from L-glutamic acid and 64Zn oxide enriched stable light isotope to 99.2% mass fraction of total zinc.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    In vitro cytotoxic activity of light stable 64Zn isotope compounds against human breast cancer cells of the luminal MCF-7 (A) and basal MDA-MB-231 (B) cell line subtypes. *p<0.05 as compared to cells treated with Zn64 sulfate. Zn64 asp, Zn64 aspartate; Zn64 glu, Zn64 glutamate; Zn64 sulf, Zn64 sulfate.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    In vitro cytotoxic activity of light stable 64Zn isotope compounds against human lung cancer cells (A-549 cell line). *p<0.05 as compared to cells treated with Zn64 sulfate. Zn64 asp, Zn64 aspartate; Zn64 glu, Zn64 glutamate; Zn64 sulf, Zn64 sulfate.

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7.

    In vitro cytotoxic activity of light stable 64Zn isotope compounds against human acute leukemia cells (HL-60 cell line). *p<0.05 as compared to cells treated with Zn64 sulfate. Zn64 asp, Zn64 aspartate; Zn64 glu, Zn64 glutamate; Zn64 sulf, Zn64 sulfate.

  • Figure 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 8.

    In vitro cytotoxic activity of light stable 64Zn isotope compounds against murine melanoma cells (MB16 cell line). *p<0.05 as compared to cells treated with Zn64 sulfate. Zn64 asp, Zn64 aspartate; Zn64 glu, Zn64 glutamate; Zn64 sulf, Zn64 sulfate.

  • Figure 9.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 9.

    In vitro comparative analysis of cytotoxic activity of 64Zn aspartate (Zn64 asp) and Zn aspartate (Zn asp) with natural isotopic distribution against tumor cells of different histogenetic patterns. *p<0.05 as compared to cells the same cell line treated with Zn aspartate with natural isotopic distribution (Zn asp).

  • Figure 10.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 10.

    In vitro comparative analysis of cytotoxic activity of Zn64 (Zn64 asp) aspartate and Zn aspartate (Zn asp) against normal cells of different histogenetic origins. *p<0.05 as compared to cells the same cell line treated with Zn aspartate with natural isotopic distribution (Zn asp). #p<0.05 as compared to MDBK cells treated with Zn64 aspartate.

  • Figure 11.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 11.

    Changes in the expression of apoptosis regulatory proteins in A-549 cells after their treatment with Zn64 aspartate (Zn64 asp). The bar chart shows the densitometry results of apoptosis-associated protein bands (A). *p<0.05 as compared to control cells. Western blot images are representative of two independent experiments. Lanes 1-3 correspond to A-549 control (cells + physiological saline) and lanes 4-6 to A-549 + Zn64 aspartate (B).

  • Figure 12.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 12.

    Changes in the expression of apoptosis regulatory proteins in MB16 cells after their treatment with Zn64 aspartate (Zn64 asp). The bar chart shows the densitometry results of apoptosis-associated protein bands (A). *p<0.05 as compared to control cells. Western blot images are representative of two performed independent experiments. Lanes 1-3 correspond to MB16 control (cells + physiological saline) and lanes 4-6 to MB16 + Zn64 aspartate.

PreviousNext
Back to top

In this issue

Anticancer Research: 42 (12)
Anticancer Research
Vol. 42, Issue 12
December 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
In Vitro Anticancer Activity of the Light Stable Zinc Isotope (64Zn) Compounds
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
4 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
In Vitro Anticancer Activity of the Light Stable Zinc Isotope (64Zn) Compounds
PETER NOVAK, ALEXANDR BALAKIN, MAX TEMNIK
Anticancer Research Dec 2022, 42 (12) 5685-5698; DOI: 10.21873/anticanres.16077

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
In Vitro Anticancer Activity of the Light Stable Zinc Isotope (64Zn) Compounds
PETER NOVAK, ALEXANDR BALAKIN, MAX TEMNIK
Anticancer Research Dec 2022, 42 (12) 5685-5698; DOI: 10.21873/anticanres.16077
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Conclusion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Resveratrol Derivatives Inhibit Pro-survival Akt Signaling Pathway in Lung Cancer
  • Development of a Benzoxazine-derived Inhibitor Targeting Epithelial-to-Mesenchymal Transition in Lung Cancer
  • ITGAV Regulation of LGALS3BP-JUNB Axis Facilitates the Cell-to-Cell Adhesion and Invasiveness of Hepatic Cancer Cells
Show more Experimental Studies

Similar Articles

Keywords

  • zinc
  • light isotope
  • stable isotope
  • anticancer effect
  • cytotoxicity
  • apoptosis
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire